NeuroPace (NASDAQ:NPCE) & Perspective Therapeutics (NYSE:CATX) Financial Comparison

NeuroPace (NASDAQ:NPCE) and Perspective Therapeutics (NYSE:CATX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, earnings and risk.

Profitability

This table compares NeuroPace and Perspective Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NeuroPace	-36.74%	-205.41%	-28.29%
Perspective Therapeutics	-4,096.66%	-27.40%	-23.16%

Analyst Ratings

This is a summary of recent recommendations and price targets for NeuroPace and Perspective Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroPace	0	1	6	0	2.86
Perspective Therapeutics	0	1	8	0	2.89

NeuroPace currently has a consensus target price of $14.50, suggesting a potential upside of 25.87%. Perspective Therapeutics has a consensus target price of $15.14, suggesting a potential upside of 393.25%. Given Perspective Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Perspective Therapeutics is more favorable than NeuroPace.

Valuation & Earnings

This table compares NeuroPace and Perspective Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroPace	$65.42 million	5.26	-$32.96 million	($1.00)	-11.52
Perspective Therapeutics	$1.43 million	145.10	-$46.51 million	N/A	N/A

NeuroPace has higher revenue and earnings than Perspective Therapeutics.

Volatility & Risk

NeuroPace has a beta of 2.05, indicating that its share price is 105% more volatile than the S&P 500. Comparatively, Perspective Therapeutics has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500.

Insider and Institutional Ownership

78.8% of NeuroPace shares are held by institutional investors. Comparatively, 54.7% of Perspective Therapeutics shares are held by institutional investors. 22.2% of NeuroPace shares are held by company insiders. Comparatively, 3.5% of Perspective Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

About NeuroPace

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.

About Perspective Therapeutics

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.